3 results
To characterize safety, tolerability, pharmacodynamic effects, and pharmacokinetics of the oral sGC stimulator BAY 1021189 in addition to standard therapy for heart failure with reduced EF (HFrEF) over 12 weeks in patients with worsening chronic…
The purpose of this study is to investigate how quickly and to what extent derazantinib is absorbed (taken up), distributed, metabolized (broken down) and eliminated from the body. The pharmacokinetics of derazantinib when it is administered…
- To identify healthy volunteers that are able and willing to participate in future vaccine trials.- To install a pool of healthy volunteers ready to participate in vaccine research for infectious diseases.- To accelerate the set- up phase and…